

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Pavelka 1



**Identifying Information** 

Section 1.

### **ICMJE Form for Disclosure of Potential Conflicts of Interest**

1. Given Name (First Name) Karel	2. Surnai Pavelka	me (Last Nar	ne)		3. Date 30-June-2020	
4. Are you the corresponding author?	✓ Yes	No				
<ul><li>5. Manuscript Title</li><li>Upadacitinib versus placebo or adalimuinadequate response to methotrexate:</li><li>6. Manuscript Identifying Number (if you known to be added)</li></ul>	A subgrou					1
Section 2. The Work Under C	onsidera	tion for P	ublication			
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	g but not lin		nts, data monitoring			.) for
Section 3. Relevant financial	activitie	s outside	the submitted	work.		
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re Are there any relevant conflicts of interest fyes, please fill out the appropriate info	ibed in the port relation est? ✓	e instruction inships that Yes	ns. Use one line fo	or each er	ntity; add as many lines as you need	
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
AbbVie		<b>✓</b>			Honoraria	
Amgen		<b>✓</b>			Honoraria	
Bristol-Myers Squibb		<b>✓</b>			Honoraria	
gis		<b>✓</b>			Honoraria	
Hospira		<b>✓</b>			Honoraria	
Medac		<b>✓</b>			Honoraria	
MSD		<b>✓</b>			Honoraria	
fizer		<b>✓</b>			Honoraria	

Pavelka 2



Grant	Non-Financial Support?	Other? Comments	
		Honoraria	
		Honoraria	
ty Patents & Cop	yrights		
ned, pending or issued	d, broadly releva	nt to the work?	S ✓ No
covered above			
		nfluenced, or that give t	the appearance of
			eir disclosure statements
ent			
m will automatically g	enerate a disc <b>l</b> os	sure statement, which w	vill appear in the box
om Hospira, personal	fees from Meda	c, personal fees from MS	
	readers could point the submitted world ditions/circumstances that presonals will ask author or disclose further informatically grant automatically grant grant automatically grant gran	Fees? Support?  Ty Patents & Copyrights  The pending or issued, broadly relevant to the submitted work?  In the submitted work?  In the submitted work are present (experience) to the submitted work are present as potential of the period of the submitted work are present as potential of the period of the submitted work are present as potential of the period of the submitted work are present as potential of the period of the submitted work are present as potential of the period of the submitted work are present as potential of the subm	Support?    Honoraria   Honora

Pavelka 3



**Identifying Information** 

Section 1.

### **ICMJE Form for Disclosure of Potential Conflicts of Interest**

1. Given Name (First Name) Zoltán	2. Surnar Szekane	ne (Last Name cz	)		3. Date 30-June-2020
4. Are you the corresponding author?	Yes	<b>✓</b> No	Correspond Karel Pave	-	or's Name
<ul><li>5. Manuscript Title</li><li>Upadacitinib versus placebo or adalimuinadequate response to methotrexate:</li><li>6. Manuscript Identifying Number (if you known)</li></ul>	A subgrou				
Section 2. The Work Under C	onsidera	tion for Puk	olication		
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)?					ent, commercial, private foundation, etc.) for udy design, manuscript preparation,
Are there any relevant conflicts of inter-	est?	Yes 🗸 No	)		
Section 3. Relevant financial	activities	outside th	e submitted	work.	
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re Are there any relevant conflicts of interesting the second conflicts of the sec	ibed in the port relation est? ✓\	instructions. onships that v Yes	. Use one line fo vere <b>present d</b>	or each er	ntity; add as many lines as you need by
Name of Entity	Grant?	Personal N	lon-Financial Support	Other?	Comments
AbbVie		<b>✓</b>			Consulting fees and honoraria
Amgen		<b>✓</b>			Consulting fees and honoraria
Bristol-Myers Squibb		<b>✓</b>			Consulting fees and honoraria
Sedeon Richter		$\checkmark$			Consulting fees and honoraria
illy		<b>✓</b>			Consulting fees and honoraria
NSD		<b>✓</b>			Consulting fees and honoraria
fizer		<b>✓</b>			Consulting fees and honoraria
Roche		<b>✓</b>			Consulting fees and honoraria

Szekanecz 2



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other?	omments	
Sanofi			Cor	nsulting fees and honoraria	a
UCB			Col	nsulting fees and honoraria	a
Section 4. Intellectual Propert	y Patents & Co	oyrights			
Do you have any patents, whether plann	ed, pending or issue	ed, broadly releva	nt to the wo	rk? ☐ Yes ✓ No	
Section 5. Relationships not c	overed above				
Are there other relationships or activities potentially influencing, what you wrote i  Yes, the following relationships/cond  No other relationships/conditions/cir	n the submitted wo	rk? s are present (exp	olain below):		nce of
At the time of manuscript acceptance, jo On occasion, journals may ask authors to					e statements.
Section 6. Disclosure Statemen	nt				
Based on the above disclosures, this form below.	ા will automatically લ્	generate a disclos	sure stateme	nt, which will appear in	the box
Zoltán Szekanecz reports personal fees f personal fees from Gedeon Richter, personal fees from Roche, personal fees from Sanofi, p	onal fees from Lilly,	personal fees fror	n MSD, perso	onal fees from Pfizer, pe	

Szekanecz 3



Section 1. Identifying Informa	ation								
1. Given Name (First Name) Nemanja	2. Surname Damjanov	(Last Name)	)		3. Date 30-June-2020				
4. Are you the corresponding author?	Yes	Yes No Corresponding Author's Name  Karel Pavelka							
5. Manuscript Title Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: A subgroup analysis of a phase III randomized controlled trial in Central and Eastern 6. Manuscript Identifying Number (if you know it)									
Section 2. The Work Under Co	nsideratio	on for Pub	olication						
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including lestatistical analysis, etc.)?  Are there any relevant conflicts of interest	out not limite	ed to grants,	data monitoring			) for			
Section 3. Relevant financial activities outside the submitted work.									
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should repart there any relevant conflicts of interest of the second propriate information of	ped in the in ort relations st?	structions. ships that w	Use one line fo vere <b>present d</b>	r each ei	ntity; add as many lines as you need l				
Name of Entity	Grant•	ersonal N Fees	lon-Financial Support	Other?	Comments				
AbbVie	<b>✓</b>	<b>✓</b>			Grants and research support, consulting fees and honoraria				
Pfizer	<b>✓</b>	<b>✓</b>			Grants and research support, consulting fees and honoraria				
Roche	<b>✓</b>	<b>✓</b>			Grants and research support, consulting fees and honoraria				
Gedeon Richter		<b>✓</b>			Consulting fees and honoraria				
Merck		<b>✓</b>			Consulting fees and honoraria				
Novartis		<b>7</b>			Consulting fees and honoraria				

Damjanov 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Nemanja Damjanov reports grants and personal fees from AbbVie, grants and personal fees from Pfizer, grants and personal fees from Roche, personal fees from Gedeon Richter, personal fees from Merck, personal fees from Novartis, outside the submitted work.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Damjanov 3



Section 1. Identifying Inform	nation							
1. Given Name (First Name) Branimir	2. Surname (Last Name) Anić	3. Date 30-June-2020						
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Karel Pavelka						
5. Manuscript Title Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: A subgroup analysis of a phase III randomized controlled trial in Central and Eastern 6. Manuscript Identifying Number (if you know it)								
Section 2. The Work Under Co	onsideration for Public	ation						
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,						
Section 3. Relevant financial	activities outside the s	ubmitted work.						
of compensation) with entities as descr	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by e present during the 36 months prior to publication.						
Section 4. Intellectual Proper	rty Patents & Copyric	ıhts						
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No						

Anić 2



Section 5.									
Section 5.	Relationships not covered above								
	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?								
Yes, the follow	Yes, the following relationships/conditions/circumstances are present (explain below):								
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest								
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.								
Section 6.	Disclosure Statement								
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box								
Dr. Anić has notł	ning to disclose.								

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Anić 3



Section 1. Identifying Inform								
Identifying Information	ation							
1. Given Name (First Name) Matija	2. Surna Tomšič	me (Last Nam	e)		3. Date 30-June-2020			
4. Are you the corresponding author?	Yes	✓ No	Correspond Karel Pave	•	or's Name			
5. Manuscript Title Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: A subgroup analysis of a phase III randomized controlled trial in Central and Easte 6. Manuscript Identifying Number (if you know it)								
Section 2. The Work Under Co	nsidera	tion for Pu	blication					
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interests.	but not lin		s, data monitoring		ent, commercial, private foundation, etc.) for tudy design, manuscript preparation,			
Section 3. Relevant financial activities outside the submitted work.								
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report there any relevant conflicts of interest of the propriate info	oed in the ort relationst?	e instructions onships that Yes \(\sum \) N	s. Use one line fo	or each e	ntity; add as many lines as you need by			
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
AbbVie	<b>V</b>	<b>√</b>			Research grants, consulting fees, and honoraria			
Amgen	<b>✓</b>	<b>✓</b>			Research grants, consulting fees, and honoraria			
Biogen	<b>✓</b>	<b>✓</b>			Research grants, consulting fees, and honoraria			
Celltrion	<b>✓</b>	<b>✓</b>			Research grants, consulting fees, and honoraria			
illy	<b>V</b>	<b>✓</b>			Research grants, consulting fees, and honoraria			

Tomšič 2



Name of Entity	Grant?		Non-Financial	Other?	Comments		
Novartis	<b>✓</b>	Fees •	Support !		Research grants, consulting fees, and honoraria		
Pfizer	<b>✓</b>	<b>✓</b>			Research grants, consulting fees, and honoraria		
Roche	<b>✓</b>	<b>/</b>			Research grants, consulting fees, and honoraria		
Sanofi	<b>✓</b>	<b>✓</b>			Research grants, consulting fees, and honoraria		
Section 4. Intellectual Property Patents & Copyrights  Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V No							
Section 5. Relationships not c	overed	above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
Yes, the following relationships/conditions/circumstances are present (explain below):							
✓ No other relationships/conditions/circumstances that present a potential conflict of interest							
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							
Section 6. Disclosure Stateme	nt						
Based on the above disclosures, this forn below.	n will auto	omatically (	generate a disclos	sure state	ment, which will appear in the box		
Dr. Tomšič reports grants and personal f from Biogen, grants and personal fees fr Novartis, grants and personal fees from outside the submitted work; .	om Celltr	ion, grants	and personal fee	s from Lil	ly, grants and personal fees from		

Tomšič 3



Section 1. Identifying Inform	nation							
1. Given Name (First Name) Vadim	2. Surname (Last Name) Mazurov	3. Date 30-June-2020						
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Karel Pavelka						
5. Manuscript Title Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: A subgroup analysis of a phase III randomized controlled trial in Central and Eastern 6. Manuscript Identifying Number (if you know it)								
Section 2. The Work Under Co	onsideration for Public	ation						
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,						
Section 3. Relevant financial	activities outside the s	ubmitted work.						
of compensation) with entities as descr	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.						
Section 4. Intellectual Proper	rty Patents & Copyric	yhts						
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No						

Mazurov 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Distribute Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Mazurov has nothing to disclose.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Mazurov 3



Section 1. Identifying Inforn	nation	
1. Given Name (First Name) Marija	2. Surname (Last Name) Maksimovic	3. Date 30-June-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Karel Pavelka
· ·	A subgroup analysis of a p	ethotrexate in patients with rheumatoid arthritis and an shase III randomized controlled trial in Central and Eastern
Section 2. The Work Under C	onsideration for Publi	cation
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descr	ibed in the instructions. Upport relations hips that we est?   Yes No	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Name of Entity	Grant	on-Financial Other? Comments
AbbVie		Employment and may own stocks
Section 4. Intellectual Prope	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, b	roadly relevant to the work? Yes V No

Maksimovic 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Marija Maksimov	vic reports personal fees from AbbVie, outside the submitted work; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Maksimovic 3



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Orsolya	2. Surname (Last Name) Nagy	3. Date 30-June-2020
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Karel Pavelka
· ·	A subgroup analysis of a p	ethotrexate in patients with rheumatoid arthritis and an shase III randomized controlled trial in Central and Eastern
Section 2. The Work Under Co	onsideration for Publi	cation
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descr	ibed in the instructions. Upport relationships that we est?	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Name of Entity	Grant	on-Financial Other? Comments
AbbVie		Employment and may own stocks
Section 4. Intellectual Proper	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, b	roadly relevant to the work? Yes V No

Nagy 2



Section 5. Relationships not solvered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Orsolya Nagy reports personal fees from AbbVie, outside the submitted work; .

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Nagy 3



**Identifying Information** 

Section 1.

Jerzy

1. Given Name (First Name)

# **ICMJE Form for Disclosure of Potential Conflicts of Interest**

Świerkot

2. Surname (Last Name)

3. Date

30-June-2020

4. Are you the corresponding author?	Yes	<b>√</b> No	Correspond Karel Pave	-	or's Name	
<ol> <li>Manuscript Title Upadacitinib versus placebo or adalimur inadequate response to methotrexate: A</li> <li>Manuscript Identifying Number (if you known)</li> </ol>	subgrou					'n
Section 2. The Work Under Co	nsiderat	tion for P	ublication			
Did you or your institution <b>at any time</b> receive any aspect of the submitted work (including l statistical analysis, etc.)? Are there any relevant conflicts of interes	ve paymen but not lim	t or services	from a third party its, data monitoring			c.) for
Section 3. Relevant financial a	ctivities	outside 1	the submitted	work.		ı
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report Are there any relevant conflicts of interesting the please fill out the appropriate information.	oed in the ort relationst?	instructior nships tha 'es	ns. Use one line fo	r each er	ntity; add as many lines as you need	d by
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
AbbVie		<b>✓</b>			Honoraria	
Amgen		<b>✓</b>			Honoraria	
Bristol Myers Squibb		<b>✓</b>			Honoraria	
Egis		<b>✓</b>			Honoraria	
Gedeon Richter		<b>✓</b>			Honoraria	
Lilly		<b>✓</b>			Honoraria	
MSD		<b>✓</b>			Honoraria	
Pfizer		<b>✓</b>			Honoraria	

Świerkot 2



W	7 Personal	Non-Financial	7	
Name of Entity	Grant Fees Fees	Support?	Other Comments	
Roche			Honoraria	
Novartis			Honoraria	
UCB			Honoraria	
Continue				
Section 4. Intellectual Propert	y Patents & Cop	yrights		
Do you have any patents, whether plann	ed, pending or issued	d, broadly relevan	t to the work? Yes	<b>√</b> No
Section 5. Relationships not o	overed above			
Are there other relationships or activities		erceive to have in	fluenced or that give the	appearance of
potentially influencing, what you wrote i	-		macricea, or that give the	appearance of
Yes, the following relationships/cond	litions/circumstances	are present (expl	ain helow):	
✓ No other relationships/conditions/cir				
	·	•		
At the time of manuscript acceptance, jo On occasion, journals may ask authors to				disclosure statements.
on occusion, journals may ush uu manio to				
Section 6. Disclosure Statemen				
Disclosure Stateme	nt			
Based on the above disclosures, this form below.	n will automatically g	enerate a disclosu	are statement, which will a	appear in the box
ociow.				
,				
Jerzy Świerkot reports personal fees fror personal fees from Egis, personal fees fro				
from Pfizer, personal fees from Roche, p				

Świerkot 3



**Identifying Information** 

Section 1.

### **ICMJE Form for Disclosure of Potential Conflicts of Interest**

Amgen  Honoraria and consulting fees	. ,	2. Surnan Petranov	ne (Last Nam va	e)		3. Date 30-June-2020	
Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and a inadequate response to methotrexate: A subgroup analysis of a phase III randomized controlled trial in Central and Eas 6. Manuscript Identifying Number (if you know it)  Section 2. The Work Under Consideration for Publication  Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation statistical analysis, etc.)?  Are there any relevant conflicts of interest? Yes No  Section 3. Relevant financial activities outside the submitted work.  Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of a of compensation) with entities as described in the instructions. Use one line for each entity, add as many lines as you not clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication for the ending of the prior of publication for the prior for publication for p	e you the corresponding author?	Yes	<b>✓</b> No		-	or's Name	
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation statistical analysis, etc.)?  Are there any relevant conflicts of interest? Yes Vo  Section 3. Relevant financial activities outside the submitted work.  Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of a of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you not clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication. Are there any relevant conflicts of interest? Yes No  If yes, please fill out the appropriate information below.  Name of Entity Grant? Personal Support? Comments  AbbVie V Honoraria and consulting fees  Amgen Honoraria and consulting fees	dacitinib versus placebo or adalimum equate response to methotrexate: A s	subgrou					
Are there any relevant financial activities outside the submitted work.    Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of a of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you not clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication. Are there any relevant conflicts of interest?	tion 2. The Work Under Con	siderat	tion for Pu	blication			
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of a of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you not clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.  Are there any relevant conflicts of interest?  Yes  No If yes, please fill out the appropriate information below.    Name of Entity	spect of the submitted work (including butical analysis, etc.)?	ut not lim	nited to grant	s, data monitoring			) for
of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you not clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.  Are there any relevant conflicts of interest?	tion 3. Relevant financial ac	tivities	outside tl	ne submitted	work.		
AbbVie  AbbVie  Amgen	mpensation) with entities as describeing the "Add +" box. You should reportered any relevant conflicts of interest	ed in the rt relation?	instructions onships that Yes \(\bigcap\) N	s. Use one line fo were <b>present d</b>	or each er	ntity; add as many lines as you need	
Amgen  Honoraria and consulting fees	e of Entity	Grant?	2	_	Other?	Comments	
Honoraria and consulting fees  MSD Honoraria and consulting fees  Novartis Honoraria and consulting fees			<b>✓</b>			Honoraria and consulting fees	
MSD Honoraria and consulting fees  Novartis Honoraria and consulting fees			$\checkmark$			Honoraria and consulting fees	
Novartis Honoraria and consulting fees			<b>✓</b>			Honoraria and consulting fees	
		П	$\overline{\checkmark}$			_	
Pfizer Honoraria and consulting fees					Ш		
			_			Honoraria and consulting fees	
Roche Honoraria and consulting fees	;		<u></u>			Honoraria and consulting fees  Honoraria and consulting fees	
Sanofi Honoraria and consulting fees	; 		✓ ✓			Honoraria and consulting fees  Honoraria and consulting fees  Honoraria and consulting fees	

Petranova 2



Name of Entity C	grant	n-Financial Other?	Comments
UCB			Honoraria and consulting fees
Section 4. Intellectual Property	Patents & Copyric	ghts	
Do you have any patents, whether planned	d, pending or issued, br	oadly relevant to the v	work? ☐ Yes  ✔ No
Section 5. Relationships not co	vered above		
Are there other relationships or activities the potentially influencing, what you wrote in	•	rive to have influenced	d, or that give the appearance of
Yes, the following relationships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/con	ions/circumstances are	present (explain below	w):
✓ No other relationships/conditions/circu	ımstances that present	a potential conflict of	interest
At the time of manuscript acceptance, jour On occasion, journals may ask authors to d			
Section 6. Disclassive Statement			
Based on the above disclosures, this form wheelow.		rate a disclosure stater	ment, which will appear in the box
Tzvetanka Petranova reports personal fees from MSD, personal fees from Novartis, pe personal fees from UCB, outside the subm	rsonal fees from Pfizer,		

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Petranova 3



Section 1. Identifyi	ng Information	
1. Given Name (First Name) Tiina	2. Surname (Last Name) Veldi	3. Date 30-June-2020
4. Are you the corresponding a		esponding Author's Name El Pavelka
·	hotrexate: A subgroup analysis of a phase II	exate in patients with rheumatoid arthritis and an I randomized controlled trial in Central and Eastern
Section 2. The Work	CUnder Consideration for Publication	
any aspect of the submitted wo statistical analysis, etc.)? Are there any relevant confli	rk (including but not limited to grants, data mon	party (government, commercial, private foundation, etc.) for itoring board, study design, manuscript preparation,
Section 3. Relevant	financial activities outside the submi	tted work.
of compensation) with entiti	es as described in the instructions. Use one I should report relationships that were <b>pres</b>	you have financial relationships (regardless of amount line for each entity; add as many lines as you need by sent during the 36 months prior to publication.
Section 4. Intellectu	ıal Property Patents & Copyrights	
Do you have any patents, wh	nether planned, pending or issued, broadly	relevant to the work? Yes V No

Veldi 2



Section 5. Relationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Tiina Veldi has nothing to disclose.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Veldi 3



Section 1. Identifying I	nformation	
1. Given Name (First Name) Asta	2. Surname (Last Name) Baranauskaitė	3. Date 30-June-2020
4. Are you the corresponding author	? Yes 🗸 No	Corresponding Author's Name Karel Pavelka
	exate: A subgroup analysis of a ph	chotrexate in patients with rheumatoid arthritis and an lasse III randomized controlled trial in Central and Eastern
Section 2. The Work Un	der Consideration for Public	ation
any aspect of the submitted work (in statistical analysis, etc.)? Are there any relevant conflicts o	cluding but not limited to grants, dat	third party (government, commercia <b>l,</b> private foundation, etc.) for a monitoring board, study design, manuscript preparation,
Section 3. Relevant fina	ncial activities outside the su	ubmitted work.
of compensation) with entities as	described in the instructions. Use	ther you have financial relationships (regardless of amount one line for each entity; add as many lines as you need by present during the 36 months prior to publication.
Are there any relevant conflicts o If yes, please fill out the appropria		
Name of Entity	Grant	-Financial Other? Comments
AbbVie	<b>V</b>	Research funding, consulting fees, and honoraria
		una nonorana
Section 4. Intellectual P	roperty Patents & Copyrig	hts
Do you have any patents, whether	er planned, pending or issued, bro	adly relevant to the work? Yes No

Baranauskaitė 2



Section 5. Relationships not solvered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Asta Baranauskaitė reports grants and personal fees from AbbVie, outside the submitted work.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Baranauskaitė 3



**Identifying Information** 

Section 1.

# **ICMJE Form for Disclosure of Potential Conflicts of Interest**

1. Given Name (First Name) Catalin	2. Surnai Codrear	me (Last Nar 1u	ne)		3. Date 30-June-2020
4. Are you the corresponding author?	Yes	<b>✓</b> No	Correspond Karel Pave	-	or's Name
<ul> <li>5. Manuscript Title</li> <li>Upadacitinib versus placebo or adalimus</li> <li>inadequate response to methotrexate: A</li> <li>6. Manuscript Identifying Number (if you known)</li> </ul>	\ subgrou				
Section 2. The Work Under Co	nsidera	tion for P	ublication		
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere	but not lin		its, data monitoring		
Section 3. Relevant financial a	activities	s outside 1	the submitted	work.	
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should repose there any relevant conflicts of interesting the serious fill out the appropriate info	oed in the ort relationst?	e instruction inships that Yes	ns. Use one line fo	or each er	ntity; add as many lines as you need by
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
AbbVie		<b>✓</b>			Consulting fees and honoraria
Amgen		<b>✓</b>			Consulting fees and honoraria
Bristol Myers Squibb		<b>✓</b>			Consulting fees and honoraria
Egis		$\checkmark$			Consulting fees and honoraria
MSD		$\checkmark$			Consulting fees and honoraria
Pfizer		<b>✓</b>			Consulting fees and honoraria
Roche		<b>✓</b>			Consulting fees and honoraria
Sanofi		<b>✓</b>			Consulting fees and honoraria

Codreanu 2



Name of Entity 0	Grant? Personal N	on-Financial Oth	er? Comments
UCB			Consulting fees and honoraria
Section 4. Intellectual Property	Patents & Copy	rights	
Do you have any patents, whether planned	d, pending or issued,	broadly relevant to	the work? ☐ Yes 🗸 No
Section 5. Relationships not co	vered above		
Are there other relationships or activities t potentially influencing, what you wrote in	-		nced, or that give the appearance of
Yes, the following relationships/condit	ions/circumstances a	re present (explain	below):
✓ No other relationships/conditions/circu	umstances that prese	nt a potential confli	ct of interest
At the time of manuscript acceptance, jour On occasion, journals may ask authors to c			ecessary, update their disclosure statements ed relationships.
Section 6. Disclosure Statemen	•		
Based on the above disclosures, this form below.		nerate a disclosure s	tatement, which will appear in the box
Catalin Codreanu reports personal fees from personal fees from Egis, personal fees from Sanofi, personal fees from UCB, outside the	n MSD, personal fees	<b>9</b> .	

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Codreanu 3



Section 1. Identifying Information								
1. Given Name (First Name) Daina	2. Surna Anderso	me (Last Name) one		3. Date 30-June-2020				
4. Are you the corresponding author?	Yes	<b>√</b> No	Correspond Karel Pave	-	or's Name			
5. Manuscript Title Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: A subgroup analysis of a phase III randomized controlled trial in Central and Eastern 6. Manuscript Identifying Number (if you know it)								
Section 2. The Work Under Co	onsidera	tion for Publ	lication					
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest? Yes Vo								
Section 3. Relevant financial a	activitie	s outside the	submitted	work.				
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .								
Are there any relevant conflicts of intere  If yes, please fill out the appropriate info	سا	Yes No						
ii yes, piease iiii out tile appropriate iiiio	IIIIatioiii	Jeiow.						
Name of Entity	Grant?	Personal No	on-Financial Support	Other?	Comments			
AbbVie	<b>✓</b>	<b>✓</b>			Grants and consulting fees			
Amgen	<b>✓</b>	<b>✓</b>			Grants and consulting fees			
Bristol Myers Squibb	<b>✓</b>	<b>✓</b>			Grants and consulting fees			
lanssen	<b>✓</b>	<b>✓</b>			Grants and consulting fees			
Novartis	<b>✓</b>	<b>✓</b>			Grants and consulting fees			
Pfizer	<b>✓</b>	<b>✓</b>			Grants and consulting fees			
Roche		<b>7</b>			Grants and consulting fees			

Andersone 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes 🗸 No
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Daina Andersone reports grants and personal fees from AbbVie, grants and personal fees from Amgen, grants and personal fees from Bristol Myers Squibb, grants and personal fees from Janssen, grants and personal fees from Novartis, grants and personal fees from Pfizer, grants and personal fees from Roche, outside the submitted work.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Andersone 3



Section 1.	Identifying Inform	ation							
1. Given Name (Fi Roy	rst Name)	2. Surnan Fleischm	ne (Last Nan nann	ne)	3. Date 30-June-2020				
4. Are you the cor	responding author?	Yes	<b>✓</b> No		Corresponding Author's Name Karel Pavelka				
5. Manuscript Title Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: A subgroup analysis of a phase III randomized controlled trial in Central and Eastern 6. Manuscript Identifying Number (if you know it)									
Section 2.	The Work Under Co	nsiderat	ion for P	ublication					
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest? Yes V No									
Section 3. Relevant financial activities outside the submitted work.									
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest?    Yes    No  If yes, please fill out the appropriate information below.									
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
AbbVie		<b>✓</b>	<b>✓</b>			Grants and consulting fees			
Amgen		<b>✓</b>	<b>✓</b>			Grants and consulting fees			
Bristol Myers Squibb		<b>✓</b>	<b>✓</b>			Grants and consulting fees			
_illy		<b>✓</b>	<b>✓</b>			Grants and consulting fees			
Novartis		<b>✓</b>	<b>✓</b>			Grants and consulting fees			
Pfizer		<b>✓</b>	<b>✓</b>			Grants and consulting fees			
EMD-Serono		<b>✓</b>				Grants			

Fleischmann 2

Grants

 $\checkmark$ 

Genentech



		B	Non Financial				
Name of Entity	Grant	Fees?	Non-Financial Support?	Other?	Comments		
Roche	<b>✓</b>				Grants		
Sanofi	<b>✓</b>				Grants		
UCB	<b>✓</b>				Grants		
Gilead	<b>✓</b>	<b>✓</b>			Grants and consulting fees		
Section 4. Intellectual Propert	y Pate	ents & Co <sub>l</sub>	pyrights				
Do you have any patents, whether plann	ed pend	ling or issue	ad broadly releva	nt to the	work? Yes V No		
bo you have any paterns, whether plann	eu, penu	iiig oi issue	ed, broadly releva	int to the	WOIK: TES Y NO		
Section 5. Polationships not a							
Relationships not c	overed	above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of							
potentially influencing, what you wrote in the submitted work?							
Yes, the following relationships/conditions/circumstances are present (explain below):							
No other relationships/conditions/circumstances that present a potential conflict of interest							
At the time of manuscript accountages in	ن بیم مام بینا	الاعداد عرباله	ve to confirm on	l :f pacac	ranu undata thair disclosura statanaanta		
At the time of manuscript acceptance, jo On occasion, journals may ask authors to							
Section 6. Disclosure Statemen							
Disclosure stateme							
Based on the above disclosures, this forn below.	า will aut	omatically	generate a disclos	sure state	ement, which will appear in the box		
Dr. Fleischmann reports grants and pers fees from Bristol Myers Squibb, grants ar							
personal fees from Pfizer, grants from EM	ИD-Seron	no, grants fr	om Genentech, g	rants fro			
from UCB, grants and personal fees from	i Gilead,	outside the	e submitted work	•			

Fleischmann 3